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Abstract
Background: Spinal cord neurons of ALS patients demonstrate reduced cytochrome oxidase histochemical activity, 
and ALS spinal cord tissues have increased mitochondrial DNA (mtDNA) point mutations and depleted mtDNA levels. It 
is presently unknown whether mtDNA abnormalities are present in single human ALS neurons.
Results: Using laser capture microdissection (LCM) we isolated several hundred individual anterior spinal neurons from 
unfixed, frozen sections of 10 ALS and 7 age-matched CTL cervical spinal cords. DNA from each individual neuron was 
analyzed with multiplex qPCR for ND2, CO3, and ND4, three mitochondrial DNA genes encoding respiratory proteins. 
Scatterplots of individual spinal neuron results showed extensive heterogeneity of mtDNA gene levels across 4-5 
orders of magnitude that were much more clustered in single Purkinje neurons isolated from CTL cerebella. Plots of 
ratios of ND4/ND2 and CO3/ND2 showed that many but not all ALS neurons from individuals contained low ratios of 
these mtDNA genes, implying greater abundances of mtDNA deletions in the major arc. Single CTL cerebellar Purkinje 
neurons did not contain high levels of apparent mtDNA deletions observed in anterior spinal neurons.
Conclusions: At the time of ALS subjects' deaths, many but not all surviving anterior neurons in their cervical spinal 
cords have reduced mtDNA gene levels and increased mtDNA deletion abundances that arise for unclear reasons. If 
these anterior spinal neuron mtDNA gene deficiencies contribute to bioenergetic impairments, reduced synaptic 
function and increased risk of degeneration, then introduction into mitochondria and expression of intact mtDNA, 
now available through use of recently developed recombinant human TFAM, may reverse the course of ALS.
Background
Impaired mitochondrial bioenergetic function is assum-
ing increasing prominence as a potential causal factor in
neuronal dysfunction and degeneration in adult neurode-
generative diseases[1-4]. Amyotrophic lateral sclerosis is
a relatively rare neurodegenerative disease of adults that
presents with a clinical phenotype deriving from progres-
sive death of upper and lower motorneurons. Spasticity,
weakness and denervation-induced muscle atrophy prog-
ress over several years to loss of swallowing and ventila-
tion function. Death ensues unless artificial ventilation is
undertaken.
90-95% of ALS occurs sporadically (sALS) and is fre-
quently associated with translocation into neuronal cyto-
plasm and aggregation of TDP-43, a normally nuclear
localized protein involved in RNA binding and process-
ing [5-9]. sALS overlaps clinically and pathologically with
frontotemporal lobar degeneration [6,7,10,11], where cas-
pase-processed TDP-43 fragments are found in cytoplas-
mic aggregates and appear to be the major toxic species
[12-14].
Surviving spinal motorneurons in ALS cases exhibit
substantial loss within their populations of histochemical
activity of cytochrome oxidase (CO) [15], the terminal
respiratory enzyme complex in the mitochondrial elec-
t r o n  t r a n s p o r t  c h a i n  ( E T C )  t h a t  i s  c o m p o s e d  o f  t h r e e
subunits coded by mitochondrial DNA (mtDNA), ten
subunits coded by nuclear DNA and utilizes critical
assembly factors also coded by nuclear genes [16]. Muta-
tions of CO subunit genes in mtDNA, nDNA or CO
assembly factors can depress CO activity [16-18], which
is selectively reduced in ALS spinal cord homogenates
[19]. ALS spinal cord tissue samples also have increased
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mtDNA point mutations and depressed mtDNA levels
[20], both of which could contribute to reduced bioener-
getic function observed in ALS motorneurons [15].
Insights into mitochondrial respiratory impairments in
ALS spinal cord neurons and homogenates can be
gleamed from complementary studies in Parkinson's dis-
ease. CO histochemically-negative substantia nigra neu-
rons from aged individuals and Parkinson's disease
subjects show increased abundances of mtDNA deletions
that can encompass CO and complex I genes and are
individually unique at their break point sequences
[21,22]. It is unclear both how those deletions arise
[23,24] and to what degree they contribute to neurode-
generation initiation and progression. Because magnetic
resonance spectroscopy studies of living PD patients at
early disease stages show reduced basal ganglia ATP lev-
els [25], mitochondrial impairments may contribute sig-
nificantly to early pathogenesis.
In the present study we measured mtDNA gene levels
in individual ALS anterior spinal neurons isolated by
laser capture microdissection (LCM). With multiplex
qPCR we determined copy numbers of ND2, CO3 and
ND4, three mtDNA genes representative of genes fre-
quently present in major arc deletions (CO3, ND4) and
normally deleted to much lesser degrees (ND2). We also
carried out identical assays in extracts from CTL cerebel-
lar Purkinje neurons as a control for the techniques used
when applied to readily recognized neurons from a popu-
lation not considered vulnerable in ALS.
Results
mtDNA ND2 gene copy numbers are equivalent in ALS and 
CTL spinal neurons
Figure 1A shows approximate locations of PCR products
generated in our qPCR assay. Figure 2A shows the cumu-
lative percentage distributions of copy numbers for the
mtDNA genes ND2, CO3 and ND4 in the ALS (n = 216
neurons) and CTL (n = 163 neurons) groups. Copy num-
bers were determined per neuron, independently of its
size. To create the cumulative analysis graphs of Figure
2A, we plotted histograms for the percentage distribu-
tions of each gene across the gene copy number ranges
shown on the x-axes. We then determined cumulative
percent distribution over each copy number interval by
adding each percent distribution to the sum of those pre-
ceding it.
In this population-based analysis there were no appar-
ent differences in ND2 copy numbers between spinal
neurons isolated from CTL compared to ALS neurons.
For CO3, the ALS population had reduced cumulative
percentages over a broad range of copy numbers. For
ND4, the ALS population had higher cumulative percent-
ages for the very low copy numbers. Figure 2A also shows
t h a t  n e u r o n s  f r o m  b o t h  g r o u p s  p o s s e s s e d  v e r y  b r o a d
ranges of mtDNA gene copy numbers, spanning many
orders of magnitude.
Data presentations as in Figures 2A and 3A have the
simplicity of displaying results for both populations stud-
ied (ALS, CTL), but they have the drawback of not show-
ing any details of distributions within each sample. These
details of each sample are revealed in the plots of Figures
4A, 5A, 6A and 7A. Additional File 1 provides the data for
each sample's individual neurons' ND2 copy numbers,
and ND4/ND2 and CO3/ND2 ratios.
mtDNA gene deletions are increased in ALS spinal neurons
To estimate relative levels of mtDNA gene deletions we
used each neuron's level of ND2 as a marker for overall
mtDNA abundance, since deletions in the minor arc
region are less common than those involving the major
arc. We expressed ratios of CO3/ND2 and ND4/ND2 as
estimates of degree of deletion involving the major arc
region where each of these genes (CO3, ND4) is located.
If all individual deletions present involved both ND4 and
CO3, then their abundances should equal each other.
However, that was not the case.
Figure 3A shows cumulative percentage plots for ND4/
ND2 and CO3/ND2 on the y-axes and fraction intact
mtDNA on the x-axes. In both graphs the ALS group
overall had greater apparent deletion abundance, but with
different distributions. For ND4 in the ALS group there
was an approximate doubling of deletions present at very
high abundance (80-90%), whereas for CO3 the ALS pop-
ulation showed a consistent increase in all deleted species
between 20-80% abundance.
Figure 1 Approximate location of the PCR products used for 
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mtDNA copy numbers and deletion abundances are very 
heterogeneously distributed
In Figures 4A and 5A the distributions of ND4/ND2 and
CO3/ND2 ratios for each neuron are shown as a function
of the individual levels of ND2 in each spinal cord sample
from the CTL and ALS populations. Figures 4A and 5A
demonstrate the extensive heterogeneity of mtDNA gene
levels observed across five orders of magnitude in all spi-
nal cord samples, the clustering (or lack thereof) among
neurons from individual spinal cords, and the relation-
ships across spinal cord samples between ND2 copy
numbers and deletion abundances involving ND4 com-
pared to CO3.
For apparent deletions involving ND4 (Figure 4A), sam-
ples with high deletion abundances (i.e, ND4/ND2 ratios
< 0.2) were distributed in CTL samples across ~2 orders
of magnitude of ND2 levels, but were both much more
abundant and distributed across ~5 orders of magnitude
of ND2 levels in the ALS population.
For apparent deletions involving CO3 (Figure 5A), sam-
ples with high deletion abundance (CO3/ND2 ratios <
0.2) were relatively rare in the CTL group but more abun-
dant in the ALS group, where they tended to cluster in
the midrange of ND2 copy number levels.
mtDNA deletions in ALS spinal neurons can be greater in 
either ND4 or CO3 and appear to relate to ND2 copy 
number levels
Figure 6A shows data extracted from Figures 4A and 5A
for selected spinal cord samples of the ALS population.
For two samples (63693, 63470), relative deletion abun-
dances were greater for ND4 compared to CO3, whereas
for two other samples (56550, 63835) the opposite was
the case. Also, for the two samples with higher apparent
levels of deletions involving ND4 compared to CO3, their
copy number levels were orders of magnitude higher than
for the two samples where deletions involving CO3
appeared more abundant than those involving ND4.
Figure 2 Cumulative percentages of copy numbers for ND2, CO3 and ND4 genes in individual anterior spinal neurons from the ALS and 
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ND2 copy numbers and apparent deletions involving ND4 
and CO3 are different in Purkinje neurons
We applied the same approach to cerebellar Purkinje
neurons isolated from four disease-free CTL cases. Fig-
ure 7A shows that the distributions in 147 Purkinje neu-
rons of ND2 copy numbers and levels of apparent
deletions involving ND4 or CO3 were much more
restricted than those found in anterior spinal neurons
from either the ALS or CTL cases. In Purkinje neurons,
apparent deletions involving ND4 tended to cluster in the
20-40% range, and those involving CO3 in the 10-30%
range.
Discussion
In this study we used multiplex qPCR to measure the lev-
els of three mtDNA protein coding genes in anterior spi-
nal neurons from cervical cord samples of ALS patients
or age-matched CTL's. Using levels of ND2 as a reference
for mtDNA copy number, we found wide variations
across five orders of magnitude in the samples. For some
subjects, levels of ND2 in individual neurons tended to
cluster together, whereas for other subjects there was
greater spread in ND2 levels and little apparent cluster-
ing. In the ALS population, cases where many neurons
contained very high deletion abundances tended to have
the most widespread distributions of ND2 copy numbers.
Identical analyses of single Purkinje neurons from four
CTL cases suggested that our techniques were not likely
sources of artifacts to explain our observations.
Our findings suggest that anterior spinal neurons from
older persons show widespread distributions of mtDNA
gene copies, whereas such diversity is less apparent in
Purkinje neurons. To our knowledge, ours is the first
study to quantitate copy numbers of multiple individual
mtDNA genes in isolated single neurons from human
postmortem specimens. mtDNA is replicated using a
RNA-primed DNA polymerase gamma [26-28], and the
control of mtDNA levels is believed to reside in a multi-
transcription factor "mitochondrial biogenesis" program
[29-31]. It is not clear why anterior spinal neurons would
show such diversity of mtDNA gene levels, which for
many samples spanned several orders of magnitude and
for others were very tightly clustered. Our findings indi-
cate that study of mitochondrial transcription factors'
gene expressions in these spinal neurons, particularly
PGC-1α, NRF1, NRF2 and PRC [29,30,32] might be help-
ful in understanding the wide variations in mtDNA gene
levels observed.
In the ALS samples we found both greater abundances
of apparent deletions involving ND4 and CO3 and varia-
tions across spinal cord samples as to which gene was
more deleted. mtDNA gene deletions have been reported
to increase with aging in human substantia nigra neurons
and become dominant in samples obtained from persons
>80 years old at time of death [21,22]. Our mean age for
the ALS specimens was 63 years, and we observed no
relationship between apparent deletion abundance and
subject age. The three ALS specimens with the greatest
numbers of very high ND4 deletion levels were from indi-
viduals who died at 50, 61 and 62 years of age.
The origins of mtDNA deletions may involve replica-
tion errors induced by repair of oxidatively damaged
bases [23,24]. Substantia nigra neuron mtDNA deletions
are characterized by an abundance of direct repeat
sequences at the deletion break points [21-23], suggesting
that DNA polymerase gamma may "skip" to similar
sequences if single strand breaks generated during repair
of oxidative damage persist during mtDNA replication.In
our study we did not attempt sequencing of mtDNA dele-
tion breakpoints, so we cannot propose whether a similar
mechanism might be operative in anterior spinal neu-
rons.
Our findings suggest that in individual ALS anterior
spinal neurons from some but not all subjects, and to a
Figure 3 Cumulative percentages for ratios of ND4/ND2 and 
CO3/ND2, estimating relative abundances of deletions in ND4 
and CO3, respectively, in individual anterior spinal neurons from 
the ALS and CTL populations.Keeney and Bennett Molecular Neurodegeneration 2010, 5:21
http://www.molecularneurodegeneration.com/content/5/1/21
Page 5 of 9
lesser extent in age-matched CTL spinal neurons, very
high abundance mtDNA deletions exist that would be
predicted to produce impaired respiratory capacity, simi-
lar to what has been observed in individual substantia
nigra neurons [21,22]. It is not clear if this situation is
causal for anterior spinal neuron death in ALS, but the
severity of the anticipated respiratory deficit would be
both substantial and markedly reduce capacity for synap-
tic activity. Such neurons would also be predicted to have
decreased capacity to modulate swings in cytosolic cal-
cium levels and survive excitotoxic stresses.
Our findings support the concept that some spinal neu-
rons die in ALS because of accumulation of high abun-
dance mtDNA deletions that are predicted to eliminate
meaningful mitochondrial ATP production. Although it
is not clear how these mtDNA deletions arise, effective
therapy would involve supplementation of intact mtDNA
to mitochondria in vivo [33].
Figure 4 Scatterplots relating the ND2 copy numbers to ratios of ND4/ND2 in the CTL (left) and ALS (right) individual anterior spinal neu-
rons.
Figure 5 Scatterplots relating the ND2 copy numbers to ratios of CO3/ND2 in the CTL (left) and ALS (right) individual anterior spinal neu-
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For treating ALS, where many neurons show complete
loss of detectable ND4 or CO3, it will likely be necessary
to provide to and express intact mtDNA in motorneu-
rons. However, it is important to note that based on our
findings, such an approach might not be effective for all
ALS subjects. Some of our cases showed abundant
mtDNA copy numbers and relatively low levels of dele-
tions. This observation speaks to the heterogeneity of a
complex disease such as ALS, and we do not propose
accumulation of mtDNA deletions as a universal cause of
synaptic failure or neurodegeneration in this condition.
Future studies need to address how such apparent
mtDNA deletions arise, whether there are failures in the
mitochondrial biogenesis program in aging neurons, and
if so, do they arise from genetic, epigenetic or post-trans-
lational causes (or some combination). From a therapeu-
tic development perspective, it is necessary to show that
rhTFAM can deliver and express intact mtDNA to ante-
rior spinal neurons and that mitochondrial respiratory
capacity in those neurons is increased.
Conclusions
Using multiplex qPCR we measured levels of ND2, CO3
and ND4, three mtDNA genes that code for essential
respiratory proteins, in individual human anterior spinal
neurons laser captured from cervical spinal cords of age-
matched ALS and CTL subjects. We found a widespread
distribution of mtDNA gene levels that could not be
accounted for solely by the techniques used. Estimated
mtDNA deletions involving either ND4 or CO3 genes
were increased in the ALS group, involved either ND4 or
CO3 to a greater extent in each subject, and were not
always predictable based on mtDNA copy numbers.
Although the origins of such deletions are not clear, those
of very high abundance are predicted to impair respira-
tion and may increase vulnerability to neurodegenera-
tion. Introduction of intact mtDNA to these neurons is
potentially therapeutic but likely would not improve spi-
nal neurons with low deletion abundance and non-
depressed mtDNA copy numbers.
Methods
Tissue and Laser Capture Microdissection
Frozen specimens of cervical spinal cord from six neuro-
logically normal, one case without motorneuron disease
but felt to have Alzheimer's dementia, and ten ALS
patients were obtained from the National Disease
Research Interchange, Philadelphia, PA http://www.ndri-
resource.org. The clinical features of these cases are listed
in Additional File 2 Table S1.Ten micron frozen sections
of unfixed spinal cord were placed on uncoated glass
microscope slides and stored at -80°C. In preparation for
laser capturing, slides were air dried 2 min. at room tem-
perature, stained for 7 min in 1% methylene blue (Elec-
tron Microscopy Sciences, Hatfield, PA), dehydrated for 2
min. each in 70 and 95% ethanol, 4 min each in 100% eth-
anol and xylenes and held in a desiccated chamber. Single
motor neurons in the anterior grey matter were dissected
using an Arcturus PixCell IIe system (Molecular Devices,
Sunnyvale, CA).
DNA Extraction and Real-Time Quantitative PCR
The DNA from each neuron was extracted using an over-
night incubation at 65°C in 50 ul TK buffer (0.5 M Tris-
HCl, pH 8.9, 20 mM EDTA, 10mM NaCl, 5% (v/v) Tween
20 and 2 mg/ml Proteinase K).Extracted samples were
diluted 1:2 with sterile TE buffer and used as the template
in multiplex qPCR reactions targeting mitochondrial
genes. Sequences of primers and probes are listed in
Additional File 3, Table S2.qPCR was carried out with
human mtDNA copy number standards in quadruplicate
Figure 6 Scatterplots showing how individual ALS cases display relatively greater deletion abundance for CO3 compared to ND4 (63835, 
56550) or for ND4 compared to CO3 (63470, 63693).Figure 7 Scatterplots relating the ND2 copy numbers to ratios of ND4/ND2 (top) and CO3/ND2 (bottom) in cerebellar Purkinje neurons 
from four CTL cases.Keeney and Bennett Molecular Neurodegeneration 2010, 5:21
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25 ul volumes using BioRad iQ Multiplex Power Mix and
an iCycler with an iQ5 detection system (BioRad, Hercu-
les, CA). The cycling protocol details were:activation at
95°C for 5 min. followed by 50 cycles of 95°C melting for
10 sec. and 50° annealing/extension for 1 min.The copy
number standards were generated by PCR amplification
of the entire human mitochondrial genome using primers
located at the BamH1 restriction site in ND6. The iso-
lated PCR product was a single band of the appropriate
~16 kbase size. Data was analyzed using the iQ5 software
and standard curves generated from the copy number
standard.
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